Medivir

Medivir brings the Q1 webcast forward to 10 a.m. on April 30

Retrieved on: 
Monday, April 29, 2024
Nasdaq Stockholm, Cancer, Medivir, Webcast

STOCKHOLM, April 29, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET.

Key Points: 
  • STOCKHOLM, April 29, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET.
  • The webcast is brought forward as Nasdaq Stockholm closes earlier.

Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI

Retrieved on: 
Monday, April 29, 2024
Oncology, Poster, Congress, DNA, Cancer, Hepatocellular carcinoma, Patient, Medivir, ESMO, DNA repair, HCC

The abstract, titled "Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma" will be presented at the conference by Dr Hong Jae Chon, CHA Bundang Medical Center in Korea.

Key Points: 
  • The abstract, titled "Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma" will be presented at the conference by Dr Hong Jae Chon, CHA Bundang Medical Center in Korea.
  • Dr Chon is one of the investigators in the ongoing phase Ib/IIa study.
  • The presentation will include pharmacodynamic data from patients in the ongoing phase Ib/IIa clinical study with fostrox + Lenvima combination, evaluating the impact on normal liver function and DNA damage in tumor cells vs healthy cells.
  • The presentation will also include an update on efficacy endpoints as the study has continued to mature and patients have been able to stay on treatment.

FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease

Retrieved on: 
Thursday, April 25, 2024
Leg, FDA, Cancer, Hip, Medivir, Sequela, Priority review, Risk, Osteoclast, Osteoarthritis, Partnership, Depression, Disease, Obesity, Patient, Cathepsin K, ODD, Ageing, Pharmaceutical industry

The FDA defines a rare pediatric disease as a serious or life-threatening disease in which the disease manifestations primarily affect individuals aged from birth to 18 years of age.

Key Points: 
  • The FDA defines a rare pediatric disease as a serious or life-threatening disease in which the disease manifestations primarily affect individuals aged from birth to 18 years of age.
  • Pediatric diseases recognized as "rare", affect fewer than 200,000 people in the United States.
  • We are delighted that MIV-711 has been granted RPDD by the FDA with the potential to become the first approved treatment option.
  • To gain RPDD, there must be supportive data suggesting that the drug may be effective in the disease.

Change in Medivir's nomination committee before the 2024 AGM

Retrieved on: 
Monday, February 26, 2024
Medivir

STOCKHOLM, Feb. 26, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm : MVIR) today announces that that the nomination committee before the annual general meeting in May 2024 changes as follows.

Key Points: 
  • STOCKHOLM, Feb. 26, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm : MVIR) today announces that that the nomination committee before the annual general meeting in May 2024 changes as follows.
  • Anders Hallberg is leaving the nomination committee and HealthInvest Partners has declined new representation in the nomination committee.
  • Other major owners have been asked in order of size and CA Fastigheter AB has appointed Stefan Bengtsson to be part of the nomination committee before the annual general meeting in May 2024.
  • The nomination committee thus consists of:
    The 2024 Annual General Meeting of Medivir will be held on Tuesday May 7, 2024.

Pancreatic Cancer Treatments Poised for Major Advances in 2024

Retrieved on: 
Wednesday, February 7, 2024
Gemcitabine, Pfizer, Bristol Myers Squibb, Investigational New Drug, Trial of the century, Pancreatic cancer, Patient, IND, Drug development, Incidence, ONC, FDA, SMP, TSX, BMY, Messenger, USP1, Woman, Cancer, HRD, Hope, News, Acquisition, Medivir, Oncolytics Biotech, PD-1, Pelareorep, Senior, TGF, Pancreatic Cancer Action Network, Pharmaceutical industry

VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group  -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).

Key Points: 
  • VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer .
  • As well, the deadly disease showed pancreatic cancer rates rising faster among women , causing increased alarm amongst doctors.
  • After closing out 2022 with another fast track designation , Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer.
  • The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award .

Pancreatic Cancer Treatments Poised for Major Advances in 2024

Retrieved on: 
Wednesday, February 7, 2024
Gemcitabine, Pfizer, Bristol Myers Squibb, Investigational New Drug, Trial of the century, Pancreatic cancer, Patient, IND, Drug development, Incidence, ONC, FDA, SMP, TSX, BMY, Messenger, USP1, Woman, Cancer, HRD, Hope, News, Acquisition, Medivir, Oncolytics Biotech, PD-1, Pelareorep, Senior, TGF, Pancreatic Cancer Action Network, Pharmaceutical industry

VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group  -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).

Key Points: 
  • VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer .
  • As well, the deadly disease showed pancreatic cancer rates rising faster among women , causing increased alarm amongst doctors.
  • After closing out 2022 with another fast track designation , Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer.
  • The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award .

Medivir to present at the Redeye Fight Cancer Day

Retrieved on: 
Wednesday, January 24, 2024
Nasdaq Stockholm, Market capitalization, Partnership, Patient, Drug development, Trial of the century, Liver cancer, Cancer, Medivir, Pharmaceutical industry

STOCKHOLM, Jan. 24, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day, today January 24, 2024.

Key Points: 
  • STOCKHOLM, Jan. 24, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day, today January 24, 2024.
  • CEO Jens Lindberg will present the company and updated data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) at 15.20 CET.
  • Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.
  • Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects.

Medivir invites to a conference call today on updated data at ASCO GI and the plans moving forward for fostrox in primary liver cancer (HCC)

Retrieved on: 
Tuesday, January 23, 2024
Patient, HCC, ASCO, Poster, Cancer, Society, CMO, Webcast, Gastrointestinal tract, Medivir

The data was presented at the ASCO (American Society of Clinical Oncology) GI (Gastrointestinal Cancers) Symposium in San Francisco on January 19.

Key Points: 
  • The data was presented at the ASCO (American Society of Clinical Oncology) GI (Gastrointestinal Cancers) Symposium in San Francisco on January 19.
  • The conference call will be held today January 23, at 14.00 CET, to update on the results in the study and the plans moving forward, including feedback from extensive interactions with world renowned experts at the ASCO GI congress.
  • -  "The updated study results presented at ASCO GI has further strengthened our belief in the combination of fostrox + Lenvima as a potential treatment for patients with advanced HCC.
  • The conference also enabled extensive interactions with global experts in HCC which provided important input regarding the design of our upcoming study.

Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium

Retrieved on: 
Wednesday, January 17, 2024
Patient, HCC, ASCO, Poster, Society, Cancer, BCLC, CMO, Safety, Hepatocellular carcinoma, Webcast, Gastrointestinal tract, Medivir, Pharmaceutical industry

-     "We are excited by these results in a poor prognosis patient population where low disease control and response rates are usually seen.

Key Points: 
  • -     "We are excited by these results in a poor prognosis patient population where low disease control and response rates are usually seen.
  • The updated data presented at ASCO GI has further strengthened our belief in the combination of fostrox + Lenvima as a potential treatment for patients with advanced HCC.
  • These data show that fostrox + Lenvima have encouraging results related to clinical outcome in patients with second-line advanced HCC without jeopardizing safety.
  • The poster will be available on Medivir's website after it has been presented at ASCO GI.

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Retrieved on: 
Monday, January 15, 2024
Patient, HCC, Poster, Cancer, EASL, Hepatocellular carcinoma, Liver cancer, Medivir, Pharmaceutical industry

STOCKHOLM, Jan. 15, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical pharmacokinetic (PK) data from the first study with fostroxacitabine bralpamide (fostrox) (NCT03781934) will be presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit in February 22-24, 2024 in Rotterdam.

Key Points: 
  • STOCKHOLM, Jan. 15, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical pharmacokinetic (PK) data from the first study with fostroxacitabine bralpamide (fostrox) (NCT03781934) will be presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit in February 22-24, 2024 in Rotterdam.
  • The abstract, titled 'Population pharmacokinetic modeling of orally administered fostroxacitabine bralpamide (fostrox, MIV-818) and its metabolite troxacitabine in a phase I/IIa liver cancer study' will be presented at the conference by Karin Tunblad PhD, Project Director for fostrox at Medivir.
  • The presentation will include pharmacokinetic results from 42 patients in the phase I/IIa clinical study with fostrox monotherapy and the fostrox + Lenvima® combination, supporting regulatory interactions and further strengthening the continued development of fostrox in patients with hepatocellular carcinoma (HCC).
  • The abstract and the poster will be available on Medivir's website after the presentation.